Navigation Links
ULURU Inc. Extends the European Altrazeal® License to Include the Middle East and Africa
Date:1/17/2012

ADDISON, Texas, Jan. 17, 2012 /PRNewswire/ --ULURU Inc. (NYSE AMEX: ULU), announced today that it has extended the previously announced European license for Altrazeal® to include the Middle East and North Africa.

Commenting on the extension of the territory, Helmut Kerschbaumer Chairman of Melmed Holdings AG, stated, "This is a territory where Melmed Holdings AG has experience marketing to the various sectors in these markets. We have an extensive network of marketing partners and contacts to penetrate this market. In addition, there are various European organizations that provide humanitarian aid to numerous markets that can be accessed to quickly establish a market presence."

Altrazeal® is a scientifically engineered advanced wound dressing designed to incorporate the desired features and benefits of the ideal wound dressings. Altrazeal® competes in the advanced wound dressing market which worldwide is estimated to be $6.5 billion growing annually at 13%. Altrazeal® has demonstrated potential clinical and economic advantages in a number of chronic and acute wounds including diabetic foot ulcers, venous ulcers and geriatric wounds.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system.  For further information about ULURU Inc., please visit our website at www.uluruinc.com.  For further information about Altrazeal®, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended.  These statements are subject to numerous risks and uncertainties, including but not limited to our belief that Altrazeal® will be a major competitor in the wound care market, the ability to quickly establish a market presence, the cost effectiveness and cost savings of Altrazeal® in healing chronic wounds, and Altrazeal®'s clinical and economic advantage and to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Extends the European Altrazeal® License to Include Australia and New Zealand
2. ULURU Inc. Receives Notice From NYSE Amex Regarding Continued Listing Standards
3. ULURU Inc. Reports Third Quarter 2011 Financial Results
4. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2011 and to Provide a Business Update
5. ULURU Inc. Announces Altrazeal® Agreement for the European Market
6. ULURU Inc. Receives NYSE Amex Notice of Non-Compliance with Continued Listing Standards
7. ULURU Inc. Enters Into Strategic Financings of Up to $1.6 Million at a Premium to Current Share Price
8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Second Quarter Ended June 20, 2011 and to Provide a Business Update
9. ULURU Inc. Announces Reverse Stock Split
10. ULURU Inc. Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor
11. ULURU Inc. Announces Voting Results of Reconvened Annual Meeting of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Iowa , Feb. 11, 2016  Proliant Biologicals ... Zealand Bovine Serum Albumin (BSA) manufacturing facility.  The facility ... New Zealand , in Feilding. ... was done to functionally duplicate the systems in the ... same vendors used for U.S. installations.  --> ...
(Date:2/11/2016)... , Feb. 11, 2016  Attending college is ... those with type 1 diabetes, the journey can be ... schedules, assignments and campus activities, they also manage the ... top of that, many are living away from home ... (Foundation) Lilly Diabetes Tomorrow,s Leaders Scholarship with $100,000 ...
(Date:2/11/2016)... Brain Cancer patients in the Mid-South now ... Cancer Center . Optune™, a portable device ... replication causing death of cancer cells, is the first ... a significant extension in overall survival rates for newly ... Center is the only medical center in ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... ... trainer and author Ray Clarke poses a question as a challenge for his ... his book, "Being in the Being" (published by Partridge Singapore), Clarke explores the ...
(Date:2/11/2016)... ... February 11, 2016 , ... AccuVein Inc. announces the Infusion ... of Practice, to include vascular visualization as a standard practice. AccuVein ( http://www.accuvein.com ... the market, facilitates adherence to this standard with its easy to use, widely ...
(Date:2/11/2016)... ... February 11, 2016 , ... Pixel Film Studios brings ... with customizable backdrops in the Christmas edition of the ProDrop series. Pick and choose ... audiences and invoke the spirit of Christmas using ProDrop's wintry generators. ProDrop Christmas is ...
(Date:2/11/2016)... ... 11, 2016 , ... Food Labeling for American Heart Month ... best practices in the past couple of decades, and food manufacturers and distributors ... which acts as an exceptional opportunity to revise food labels and stickers to ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... (WMIS), known as the World Molecular Imaging Congress (WMIC), will be held in ... the 2016 meeting is “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize ...
Breaking Medicine News(10 mins):